MacroGenics (NASDAQ:MGNX - Get Free Report) will likely be announcing its earnings results before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($0.54) per share and revenue of $34.17 million for the quarter.
MacroGenics Price Performance
Shares of MGNX traded up $0.06 on Friday, reaching $2.46. The company's stock had a trading volume of 522,739 shares, compared to its average volume of 661,573. The stock has a market capitalization of $154.40 million, a P/E ratio of -1.56 and a beta of 2.02. MacroGenics has a 12-month low of $2.33 and a 12-month high of $21.88. The stock's 50 day simple moving average is $2.98 and its two-hundred day simple moving average is $3.35.
Analyst Ratings Changes
A number of analysts have commented on MGNX shares. HC Wainwright restated a "neutral" rating and issued a $4.00 price target on shares of MacroGenics in a research report on Wednesday, November 6th. StockNews.com upgraded MacroGenics from a "sell" rating to a "buy" rating in a report on Sunday, November 10th. Finally, JMP Securities downgraded shares of MacroGenics from an "outperform" rating to a "market perform" rating in a report on Thursday, November 7th. Eight analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $7.63.
Get Our Latest Research Report on MacroGenics
MacroGenics Company Profile
(
Get Free Report)
MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.
Featured Stories
Before you consider MacroGenics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MacroGenics wasn't on the list.
While MacroGenics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
